VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update
VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update PR Newswire Conference call to discuss financial and operational results scheduled for Thursday, March 31 , at 8:00am U.S. Eastern Time · Executed more...
Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results and Provides Corporate Update
Twirla Demand Grows with Cycles Dispensed and Total Prescriptions (TRx) Up 35% and 33% Respectively in Fourth Quarter 2021 vs Third Quarter 2021 New Twirla Connected TV Commercial Expected to launch in April 2022 and more...
Cutera (CUTR) Upgraded to Buy: Here’s Why
Cutera (CUTR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates — one more...
Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to more...
Avinger Announces Issuance of Three New U.S. Patents in March 2022
16 New U.S. and International Patents Issued over Past Year REDWOOD CITY, CA / ACCESSWIRE / March 30, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only more...
CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results
– Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance – Focus on Pharma and Diagnostics to Position for Strong Performance in 2022 – Closed $62 Million Financing more...
New Strong Sell Stocks for March 30th
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Alimera Sciences ALIM is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Zacks more...
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates
Infinity Pharmaceuticals (INFI) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.17 per share a year ago. These more...
Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Misses Revenue Estimates
Motus GI Holdings, Inc. (MOTS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago. These figures more...
Verint Systems (VRNT) Q4 Earnings Lag Estimates
Verint Systems (VRNT) came out with quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.98 per share a year ago. These figures are more...